Tiziana: Foralumab Drug Development Presses On With Additional EAP Enrollment
Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.
Targeted Oncology5h
FDA OKs Trial of Novel CAR T-Cell Therapy in T-ALL/LBL
The “off-the-shelf” CAR T-cell therapy CTD402 will be evaluated in a phase 1b/2 trial for patients with T-cell acute ...
Tiziana Life Sciences files IND application with FDA for ALS Phase 2 trial
Tiziana Life Sciences (TLSA) announced the submission of its Investigational New Drug, IND, application to the U.S. Food and Drug ...
Yahoo Finance9d
Oncotelic Accesses Rapid IND Development Platform through Partnership with Medicilon
AGOURA HILLS, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC). Oncotelic Therapeutics Inc., a leader in RNA-based therapeutics ...
Oncotelic Accesses Rapid IND Development Platform through Partnership with Medicilon
Enabling Rapid Growth: Medicilon’s integrated platform for drug discovery, pharmaceutical research, and preclinical development will expedite the regulatory pathways for Oncotelic’s and SAPU’s ...
The Manila Times2d
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.
Tiziana Life Sciences Ltd.: Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
NEW YORK, March 04, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...
Vericel: Scalable Growth With Strong Margins
Vericel's FDA-approved regenerative medicine products and robust pipeline signal strong growth potential, with zero debt and ...